• About
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs (Frequently Asked Questions)
    • ICNMD 2021 FAQs
    • Related Events
    • Contact
  • Program
    • Program at a Glance
  • Sponsorship
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • ICNMDigital Program
    • Virtual Congress FAQs
    • CME Accreditation
    • ICNMDigital Industry-Supported Symposia
    • Registration
    • ICNMD 2021 Preliminary Congress Agenda
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs
    • Related Events
    • Contact
    • Program at a Glance
    • Registration
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • Venue Information
    • Travel Information
    • Valencia Information
    • Contact
    • Past Congresses
MENU
  • About ICNMD
  • Past Congresses
  • Contact
  • About
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs (Frequently Asked Questions)
    • ICNMD 2021 FAQs
    • Related Events
    • Contact
  • Program
    • Program at a Glance
  • Sponsorship
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • ICNMDigital Program
    • Virtual Congress FAQs
    • CME Accreditation
    • ICNMDigital Industry-Supported Symposia
  • About ICNMD
  • Past Congresses
  • Contact
  • #ICNMD2021
  • Facebook
  • Twitter
  • Linkedin
  • About
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs (Frequently Asked Questions)
    • ICNMD 2021 FAQs
    • Related Events
    • Contact
  • Program
    • Program at a Glance
  • Sponsorship
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • ICNMDigital Program
    • Virtual Congress FAQs
    • CME Accreditation
    • ICNMDigital Industry-Supported Symposia
Get Tickets!

Industry-Supported Symposia

  • Registration
  • ICNMD 2021 Preliminary Congress Agenda
  • Sponsorship Opportunities
  • Confirmed Supporters
  • Industry-Supported Symposia
  • Sponsorship Opportunities
  • Confirmed Supporters
  • Industry-Supported Symposia

Sponsored Content

Sponsored Content

 

Stay in the Know
Get the latest news on exciting speakers, workshops & learning opportunities at ICNMD 2021.

Subscribe for Updates

Tweets by ICNMD 2021

The following industry-supported symposia, organized by ICNMD 2021 sponsors, will be broadcast live on the following days and times. Click on the tabs below to read more.

During ICNMD 2021 Live Days, you will find these symposia listed chronologically in the 'Industry Sessions' section of the virtual platform.

Starting May 17, you may also click on the dedicated symposium links [which will be provided below] to be taken directly to each symposium page. You will need to log in with your platform credentials (to be sent on May 17 to ICNMD 2021 registered delegates).

 

Friday, 21 May
Saturday, 22 May
Friday, 28 May
Saturday, 29 May
Generalised Myasthenia Gravis (gMG) 360: From Cause to Consequence
Time: 12:00 - 12:45 CEST
Agenda
  • Introduction
    Prof. John Vissing, Professor of Neurology; Director, Neuromuscular Clinic and Research Unit, Department of Neurology, University of Copenhagen, Denmark (Chair)
  • Initial outlook: The immune system in rare autoimmune neuromuscular diseases
    Prof. Heinz Wiendl, Head of Department, Chair, Department of Neurology, Institute of Translational Neurology, University Hospital Muenster, Germany
  • Full circle: Clinical consequences of gMG
    Prof. John Vissing
  • Q&A
    All
  • Closing the loop
    Prof. John Vissing

A Novel Assessment of Swallowing in SMA: Insights from the NURTURE Study 
Time:
 12:00 - 12:20 CEST
Agenda
  • A Novel Assessment of Swallowing in SMA: Insights from the NURTURE Study
    Prof. Valeria Sansone, NEuroMuscular Omnicentre (NEMO), Italy
  • Live Q&A

Current Treatment Landscape of Myotonia in Muscle Channelopathies: Focus on Mexiletine
Time: 12:25 - 12:45 CEST
Agenda

Speaker: Prof Savine Vicart, University Hospital Pitié-Salpêtrière, France

  • Overview on unmet medical needs in non-dystrophic myotonia, NDM
  • Phase 3 clinical trial outcomes, MYOMEX Study
  • NaMuscla (mexiletine) is an approved anti-myotonic in NDM
  • Summary and challenges in NDM management

Gene Therapy – Transforming the Clinical Outlook for Neuromuscular Diseases
Time: 17:15 - 18:00 CEST
Agenda
  • Welcome & Introduction – Challenges of Early Treatment in Neuromuscular Diseases
    Prof Laurent Servais, Professor of Paediatric Neuromuscular Diseases – MDUK Oxford Neuromuscular Centre, UK, and Invited Professor of Child Neurology, Liège University, Belgium
  • Potential of Gene Therapy for Neuromuscular Diseases
    Dr Janbernd Kirschner, Department of Neuropediatrics, University Hospital Bonn, Germany
  • Capturing the Clinical Perspective on Gene Therapy
    Sandra P. Reyna, VP, Global Medical Affairs, Novartis Gene Therapies, USA (Moderator)
    Prof Laurent Servais and Dr Janbernd Kirschner
  • Closing & Q&A
    Sandra P. Reyna

How to Overcome Challenges in Pompe Disease Management During the COVID-19 Era
Time: 17:15 - 18:00 CEST
Agenda
  • Welcome
    Dr. Stephan Wenninger (Chair)
  • Optimizing Treatment of Pompe Disease
    Dr. Stephan Wenninger
  • A Local Perspective
    Dr. Marcelo Rugiero
  • Q&A
    Dr. Stephan Wenninger (Chair) + Dr. Marcelo Rugiero

Case Studies of Intrahepatic Cholestasis in X-linked Myotubular Myopathy
Time: 12:00 - 12:45 CEST
Agenda
  • Overview of XLMTM
    Dr Weston Miller, Senior Medical Director, Astellas Gene Therapies, USA
  • Presentation of four cases of intrahepatic cholestasis in untreated XLMTM patients
    Dr Cristina Molera, Servicio de Gastroenterologia, Hepatologia i Nutrició Pediàtrica, Hospital Sant Joan de Deu, Spain
  • Q&A

Meaningful Outcomes Across All SMA Types
Time: 12:00 - 12:45 CEST
Agenda
  • Welcome and Introduction
    Prof. Laurent Servais (Chair) 
  • A New Chapter: Beyond Motor Function in Type 1 SMA
    Prof. Laurent Servais + Panel discussion 
  • Q&A
    All faculty 
  • Changing the Narrative: What is Meaningful in Type 2 or 3 SMA?
    Prof. Anna Kostera-Pruszczyk + Panel discussion 
  • Q&A
    All faculty 
  • Summary and Close
    Prof. Laurent Servais

Serum Autoantibody Levels and the Role of Specificity in Myasthenia Gravis
Time: 16:15 - 17:00 CEST
Industry-Supported Symposium by Sarepta Therapeutics
Time: 16:15 - 17:00 CEST
Can We Regain Control? A Clinical Case-Based Discussion on the Treatment of Refractory Generalized Myasthenia Gravis
Time: 12:00 - 12:45 CEST
Agenda
  • Welcome and introductions
    Dr Carlos Casasnovas, Hospital de Bellvitge, Spain (Chair)
  • Impact of refractory generalized myasthenia gravis on patient well-being
    Dr Carlos Casasnovas, Hospital de Bellvitge, Spain
  • Complement in the pathophysiology and treatment of refractory generalized myasthenia gravis
    Dr Nico Melzer, Universitätsklinikum Düsseldorf, Germany
  • Real-world experience with refractory generalized myasthenia gravis
    Dr Hiroyuki Murai, International University of Health and Welfare, Japan
  • Questions and close
    Chair and speakers

A Unique Pregnancy Case: Venturing Beyond the Norms in Pompe Disease
Time: 12:00 - 12:20 CEST
Agenda

Speakers: Prof. Priya Kishnani, Professor of Pediatrics, Duke Department of Pediatrics, USA (chair & speaker) 
Dr. Sheela Nampoothiri, Clinical Professor & Head of Department of Pediatric Genetics, Amrita Hospital, India (speaker)

  • Welcome
  • Joint Discussion of a unique pregnancy patient case study and its related challenges and impacts in managing Pompe disease
  • Q&A

What Matters? Setting Treatment Expectations in SMA Type 1
Time: 12:25 - 12:45 CEST
Agenda
  • What Matters? Setting Treatment Expectations in SMA Type 1
    Prof. Laurent Servais, Muscular Dystrophy UK (MDUK), MDUK Oxford Neuromuscular Centre, University of Oxford, UK and University of Liege, Belgium
  • Live Q&A

Understanding the Immunomodulatory Effects and Clinical Benefits of IVIG in Myasthenia Gravis
Time: 16:15 - 17:00 CEST
Agenda
  • Introduction
    Prof. Dr. Marinos C. Dalakas (chair), Thomas Jefferson University, USA
  • The Role of IVIG in the Immunomodulation of Myasthenia Gravis
    Prof. Dr. Marinos C. Dalakas, Thomas Jefferson University, USA
  • New Data on IVIG Treatment of Myasthenia Gravis
    Prof. Dr. Andreas Meisel, Integrated Center for Myasthenia Gravis, Charité – University Medicine Berlin, Germany  
  • Q&A

Advancing the Management of Duchenne Muscular Dystrophy: The Disease Continuum and Transition from Pediatric to Adult Care
Time: 16:15 - 17:00 CEST
Agenda
  • Welcome and Introduction
    Dr. med. Christian Werner, Executive Director, Global Medical Affairs – Global DMD Lead, PTC Therapeutics (Chair)
  • DMD as a Disease Continuum: a Succession of Management Milestones
    Prof Tracey Willis, Consultant Paediatric Neurologist, The Robert Jones and Agnes Hunt Orthopaedic Hospital, England
  • The Transition from Pediatric to Adult Care for Patients with nmDMD
    Prof Thomas Sejersen, Professor in Neuropediatrics, Karolinska University Hospital and Karolinska Institute, Sweden
  • Panel Discussion and Q&A: Managing Patients with nmDMD throughout the Disease Continuum
    Moderated by Dr. med. Christian Werner (Chair)

Pathways and Paradigms in ALS: Life and Death in the Neuron 
Time: 12:00 - 12:45 CEST
Agenda
  • The role and common dysfunctions of ER and mitochondria in the neurodegenerative disorders, including ALS
  • The multiple complex pathways in ALS pathophysiology and how they lead to neurodegeneration
  • The rationale for a multipronged approach simultaneously targeting multiple pathways underlying ALS
  • Live Q&A

Suspecting, Diagnosing, and Managing Multifocal Motor Neuropathy: A Patient Investigation
Time: 17:15 - 18:00 CEST
Agenda
  • Welcome and Introduction
    Dr. Mark B. Bromberg, University of Utah, USA 
  • To Diagnose You First Have to Suspect: Establishing the Early Clues of MMN
    Dr. H. Stephan Goedee, University Medical Center Utrecht, The Netherlands 
  • The Mystery of the Pathogenesis of MMN: What Do We Know?
    Dr. Mark B. Bromberg
  • New Developments in Ig Therapy for MMN: What Matters to Patients
    Dr. Ali Al-Zuhairy, Copenhagen University Hospital, Denmark 
  • “Ask the Faculty” and Take-Home Messages
    Dr. Mark B. Bromberg, Dr. H. Stephan Goedee, and Dr. Ali Al-Zuhairy

Gene Transfer Therapy: Addressing the Unmet Needs of Duchenne Muscular Dystrophy (DMD)
Time: 17:15 - 17:35 CEST
Agenda

Speaker: Professor Wolfgang Müller-Felber, Dr von Hauner Children’s Hospital, Germany
  • Key Milestones in the History of Gene Therapy
  • An Overview of Gene Therapy
  • Gene Transfer Therapy to Treat DMD: Rationale and Challenges
  • Gene Therapy, a Once-in-a-Lifetime Treatment?
  • Summary and Close



  •  

    The ICNMD is organized on behalf of the Applied Research Group on Neuromuscular Diseases of the World Federation of Neurology.
  • Stay Connected

    Keep up to date with Conference News & Alerts.
    Sign Up

     

    #ICNMD2021

  • ICNMD2021 Conference Secretariat
    ICS International Conference Services LTD (ICS)
    300 – 1201 West Pender Street
    Vancouver, BC, Canada V6E 2V2
    P: [+1] 604 681 2153
    E: icnmd2021@icsevents.com
    Web: icnmd.org
© 2021 International Congress on Neuromuscular Diseases | Privacy Notice

Stay Up to Date!
Receive the latest information about the International Congress on Neuromuscular Diseases by entering your information below.
Thank you! We look forward to connecting soon.
Click here to close this windows
Whoops, looks like there was an issue with one of the fields above - please review above.
X